New tetanus vaccine enters first human safety tests
NCT ID NCT07598890
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new tetanus vaccine in 80 adults aged 18 and older. The study is randomized and double-blind, meaning neither participants nor doctors know who gets the new vaccine versus an existing one. The main goal is to check for side effects within the first week and month after vaccination, and to see how the immune system responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tetanus vaccine
- What this could lead to
- If successful, this could lead to a new, safe tetanus vaccine option for adults.
- What could go wrong
- This is a very early Phase 1 trial with only 80 people, so it's mainly checking safety, not yet proving the vaccine works. Many early-stage vaccines do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Can a single shot keep tetanus at bay?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Can a new tetanus shot offer stronger protection?
- Are adults in beijing still protected against tetanus? a study investigates